Multiple Myeloma Faceoff: UT Southwestern vs Mayo Clinic

Expert panelists from UT Southwestern and the Mayo Clinic introduce themselves and prepare for a team-vs-team debate surrounding recent clinical trial data in relapsed/refractory multiple myeloma.

Expert Larry Anderson, Jr, MD, PhD, FACP, reviews data from the KarMMa-3 study of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.

Panelists follow up with questions and comments on the KarMMa-3 study in relapsed/refractory multiple myeloma and consider how idecabtagene vicleucel might fit into real-world practice.

Key opinion leader Prashant Kapoor, MD, FACP, shares data from the CARTITUDE-4 study of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma.

Experts from the Mayo Clinic and UT Southwestern share insight on the CARTITUDE-4 study and ciltacabtagene autoleucel in the second cross Q&A session.

Adeel Khan, MD, MPH, MS, expert in multiple myeloma management, reviews data from the ALLIANCE A061202 trial of isatuximab + pomalidomide + dexamethasone in relapsed/refractory disease.

Panelists from both the Mayo Clinic and UT Southwestern comment on data from ALLIANCE A061202 and consider the role of isatuximab in patients with relapsed/refractory multiple myeloma.

Covering the first of two abstracts, Wilson Gonsalves, MD, reviews data from the IKEMA study of isatuximab KD in patients with relapsed/refractory multiple myeloma.

Expert Wilson Gonsalves, MD, shares clinical data in multiple myeloma centered on the distinction between biochemical versus clinical progression.

In the final cross Q&A session from the multiple myeloma module, panelists discuss implications of IKEMA and consider the importance of biochemical versus clinical progression.

UT Southwestern and Mayo Clinic debated over current treatment options in chronic myeloid leukemia and multiple myeloma.